SCIENTIFIC HUB

Follow the evidence.

107.519 articles found

Source record

The class-IIa HDAC inhibitor TMP269 promotes BMP-Smad signalling and is neuroprotective in in vitro and in vivo 6-hydroxydopamine models of Parkinson's disease.

O'Mahony AG, Mazzocchi M, Morris A, Morales-Prieto N, Guinane C, Wyatt SL, Collins LM, Sullivan AM, O'Keeffe GW.

Neuropharmacology · 2025-01-20

DOI: 10.1016/j.neuropharm.2025.110319PMID: 39842624

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Source record

Letter to the editor concerning: Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis. Limveeraprajak N, Makkapavee W, Likhitsathian S, Srisurapanont M. Possibly a greater risk?

Friedman JH.

Gen Hosp Psychiatry · 2025-01-19

DOI: 10.1016/j.genhosppsych.2025.01.010PMID: 39837260

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

Filters

Filters

Clear
Publication year
Research area
Author
Journal
Publication type
Source & language
Open accessAccess does not establish reuse rights.